Sharma, P., Krainer, M., Saad, F., Castellano, D., Bedke, J., Kwiatkowski, M., Patnaik, A., Procopio, G., Wiechno, P., Kochuparambil, S., Thomas, C., Arija, J. Ã. A., McCune, S. L., Hansen, S., Daugaard, G., Mingorance, J. I. D., Kukard, C., Subudhi, S. K., Basu, S., Jindal, S., Siddiqui, B. A., Lako, A., Gupta, S., Fedorov, V., Amin, N. P., Campos, A., Wang, Y., David, J. M., Pachynski, R. K. (2026). Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nature Communications. https://doi.org/10.1038/s41467-026-72242-w